Aimmune Therapeutics (AIMT)
Roth Capital analyst Jotin Marango reiterated a Buy rating on Aimmune Therapeutics today and set a price target of $80. The company’s shares closed yesterday at $26.16, close to its 52-week low of $24.73.
According to TipRanks.com, Marango is a 2-star analyst with an average return of 2.4% and a 39.2% success rate. Marango covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Stemline Therapeutics Inc, and Cyclacel Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aimmune Therapeutics with a $51 average price target.
Motif Bio plc (MTFB)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Motif Bio plc, with a price target of $32. The company’s shares closed yesterday at $9.01.
“Valuation methodology, risks and uncertainties. We employ a risk- adjusted net present value (rNPV) approach that yields $600M for iclaprim—with a 90% probability of success, 16% discount rate and 40% effective tax rate—and a price per share of $32.00 based on about 20M American Depositary Shares (ADSs) outstanding as of mid-2019.”
According to TipRanks.com, Selvaraju is a 1-star analyst with an average return of 0.0% and a 35.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Bausch Health Companies Inc, and Synergy Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Motif Bio plc with a $32 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.